Present and Future Treatment Strategies for Coronavirus Disease 2019

Overview

Journal Futur J Pharm Sci

Specialty Pharmacology

Date 2021 Apr 14

PMID 33850936

Citations 11

Authors

Engy Elekhnawy

Amal Abo Kamar

Fatma Sonbol

Affiliations

Soon will be listed here.

Abstract

Background: The recent pandemic of coronavirus disease 2019 (COVID-19) has resulted in many challenges to the healthcare organizations around the world. Unfortunately, until now, there are no proven effective therapeutic agents against this virus.

Main Body: Several evolving studies suggest repurposing a potential list of drugs which have appropriate pharmacological and therapeutic effects to be used in treating COVID-19 cases. In the present review, we will summarize the potential drugs suggested to be repurposed to be utilized in the treatment of COVID-19 patients like lopinavir-ritonavir, ribavirin, baloxavir marboxil, favipiravir, remdesvir, umifenovir, chloroquine, hydroxychloroquine, azithromycin, corticosteroids, losartan, statins, interferons, nitric oxide, epoprostenol, tocilizumab, siltuximab, sarilumab anakinra, and ruxolitinib. In addition, we discussed the possible future therapeutic regimens based on the recent molecular and genomic discoveries.

Conclusion: This review could provide beneficial information about the potential current and future treatment strategies to treat the pandemic COVID-19 disease.

Citing Articles

Determination of baloxavir marboxil in pharmaceutical preparations and spiked human plasma using its quenching action on acetoxymercuric fluorescein reagent: Assessment of greenness and whiteness.

Nasr M, Kaddah M, Morshedy S, Omran G, Talaat W Heliyon. 2024; 10(11):e32120.

PMID: 38912445 PMC: 11190548. DOI: 10.1016/j.heliyon.2024.e32120.

PDZ2-conjugated-PLGA nanoparticles are tiny heroes in the battle against SARS-CoV-2.

Giacon N, Lo Cascio E, Pennacchietti V, De Maio F, Santarelli G, Sibilia D Sci Rep. 2024; 14(1):13059.

PMID: 38844490 PMC: 11156922. DOI: 10.1038/s41598-024-63239-w.

Bacterial Co-Infections and Antimicrobial Resistance in Patients Hospitalized with Suspected or Confirmed COVID-19 Pneumonia in Kazakhstan.

Lavrinenko A, Kolesnichenko S, Kadyrova I, Turmukhambetova A, Akhmaltdinova L, Klyuyev D Pathogens. 2023; 12(3).

PMID: 36986292 PMC: 10052929. DOI: 10.3390/pathogens12030370.

Economic evaluation of strategies against coronavirus: a systematic review.

Izadi R, Hatam N, Baberi F, Yousefzadeh S, Jafari A Health Econ Rev. 2023; 13(1):18.

PMID: 36933043 PMC: 10024293. DOI: 10.1186/s13561-023-00430-1.

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19.

Karatas H, Hanashalshahaby E, Catal U, Butun Y, Kurt E, Gursel S Chem Zvesti. 2022; 77(3):1695-1702.

PMID: 36466109 PMC: 9685009. DOI: 10.1007/s11696-022-02595-1.

References

Wu R, Wang L, Kuo H, Shannar A, Peter R, Chou P . An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep. 2020; 6(3):56-70. PMC: 7211915. DOI: 10.1007/s40495-020-00216-7. View

Kruse R . Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 2020; 9:72. PMC: 7029759. DOI: 10.12688/f1000research.22211.2. View

Schrezenmeier E, Dorner T . Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16(3):155-166. DOI: 10.1038/s41584-020-0372-x. View

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View

Messina F, Giombini E, Agrati C, Vairo F, Bartoli T, Al Moghazi S . COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. J Transl Med. 2020; 18(1):233. PMC: 7286221. DOI: 10.1186/s12967-020-02405-w. View

DAlessio A, Del Poggio P, Bracchi F, Cesana G, Sertori N, Di Mauro D . Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. Leukemia. 2020; 35(2):635-638. PMC: 7654848. DOI: 10.1038/s41375-020-01087-z. View

Li Q, Li W, Jin Y, Xu W, Huang C, Li L . Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study. Infect Dis Ther. 2020; 9(4):823-836. PMC: 7467137. DOI: 10.1007/s40121-020-00332-3. View

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J . Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17):9490-9496. PMC: 7196837. DOI: 10.1073/pnas.2004168117. View

Chen Y, Wang A, Yi B, Ding K, Wang H, Wang J . [Epidemiological characteristics of infection in COVID-19 close contacts in Ningbo city]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41(5):667-671. DOI: 10.3760/cma.j.cn112338-20200304-00251. View

10.

Fang L, Karakiulakis G, Roth M . Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020; 8(4):e21. PMC: 7118626. DOI: 10.1016/S2213-2600(20)30116-8. View

11.

Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalco P . Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. Front Med (Lausanne). 2020; 7:170. PMC: 7193030. DOI: 10.3389/fmed.2020.00170. View

12.

Ray W, Murray K, Hall K, Arbogast P, Stein C . Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20):1881-90. PMC: 3374857. DOI: 10.1056/NEJMoa1003833. View

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

14.

Bengtson C, Montgomery R, Nazir U, Satterwhite L, Kim M, Bahr N . An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. Front Med (Lausanne). 2021; 8:630209. PMC: 7926174. DOI: 10.3389/fmed.2021.630209. View

15.

Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F . Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020; 26(11):1708-1713. DOI: 10.1038/s41591-020-1088-9. View

16.

Barh D, Tiwari S, Andrade B, Giovanetti M, Costa E, Kumavath R . Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain. F1000Res. 2020; 9:576. PMC: 7411520. DOI: 10.12688/f1000research.24074.1. View

17.

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

18.

Hu X, Hu C, Jiang D, Zuo Q, Li Y, Wang Y . Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China. Dose Response. 2021; 18(4):1559325820979921. PMC: 7745599. DOI: 10.1177/1559325820979921. View

19.

Russo V, Puzio G, Siniscalchi N . Azithromycin-induced QT prolongation in elderly patient. Acta Biomed. 2006; 77(1):30-2. View

20.

Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S . Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020; 56(3):106114. PMC: 7377772. DOI: 10.1016/j.ijantimicag.2020.106114. View